Work

Evaluation of treatments for HIV-associated Kaposi sarcoma in Africa

Year: 2021

Type: article

Abstract: To the editors:We write to comment on the recent article by Coldiron and colleagues [1] that describes Médecins Sans Frontières' programmatic use of pegylated liposomal doxorubicin (PLD) for treatment of HIV-associated Kaposi sarcoma (KS) in Mozambique.Their discussion raises the important and very pertinent issue of health systems barriers to effective and sustainable cancer treatment in low-and middle-income countries, which is a problem for all cancers, not just for KS.That said, we wish to register our concerns about some of the particulars of their study and their interpretation of the data.

Source: Infectious Agents and Cancer

DOI: 10.1186/s13027-021-00364-5

Authors: Susan E. Krown, Margaret Z. Borok

Institutions: Memorial Sloan Kettering Cancer Center, University of Zimbabwe, Parirenyatwa Hospital

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,690